Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

OX-640 is under clinical development by Orexo and currently in Phase I for Allergic Rhinitis. According to GlobalData, Phase I drugs for Allergic Rhinitis have an 81% phase transition success rate ...

Alpha- and beta-blockers reduce oxidative stress and inflammation caused by aircraft noise but fail to prevent hypertension, ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Hugging Leaf has released a new guide to the potential role of alpha and beta acids in improving sleep quality.

Newly discovered estrogen receptor-dependent signaling pathways demonstrate that estrogen functions in the cytosol as well as in the nucleus. The classic estrogen receptor signaling pathway occurs ...